Bioptimus secures $35 to develop biology research with AI

Embracing an approach in the realm of generative AI, Paris-based Bioptimus stands at the forefront with its focus on biology. Unlike general AI models, Bioptimus zooms in on biological data intricacies, tapping into a niche where quality of data takes precedence over quantity.

• Investment in Future Tech: Recognizing the scale of their ambition, Bioptimus has raised a substantial $35M seed round, acknowledging the capital demands to fund cutting-edge research and GPU-intensive model training.

• Investor Line Up: This funding was led by Sofinnova Partners with participation from Bpifrance Large Venture, Frst, Cathay Innovation, Headline, Hummingbird, NJF Capital, Owkin, Top Harvest Capital and Xavier Niel.

• Leadership: Bioptimus was founded by Rodolphe Jenatton, Zelda Mariet, Felipe Llinares, David Cahané, Eric Durand, and Jean-Philippe Vert.

• Owkin's Data Goldmine: Bioptimus is utilizing on Owkin's vast, multimodal patient datasets, garnered from top academic hospitals globally, setting the stage for benchmark-setting advancements in diagnostic procedures, precision medicine, and novel biomolecular discoveries.

• Owkin's Dream Child: Functioning alongside Owkin, yet housed as its own entity, Bioptimus represents a strategic decision for focused growth in AI model development—a moonshot project conceived for monumental strides in biology.

With Amazon Web Services in their corner, Bioptimus is poised to leverage some of the most formidable data centers for their model training endeavors.